Advanced head and neck cancer and clinical experience of an effective new agent: Docetaxel

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4751-4756

  Schoffski P ^a   Weihkopf, T ^a   Ganser, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Combination chemotherapy; Docetaxel; Head and neck cancer; Single agent chemotherapy; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; HEAD AND NECK CANCER; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION; TAXOIDS;

EID: 0032422042     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Armand JP, Couteau C: Chemotherapy in head and neck treatment. Eur J Cancer 5(31A): 819-22, 1995.
2. Vokcs EE, Weichselbaum RR, Lippman SM et al: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. Dimery IW, Hong WK: Overview of combined modality therapies for head and neck. J Natl Cancer Inst 85: 95-111, 1993.
4. Al Sarraf M. Head and neck cancer: Chemotherapy concepts. Semin Oncol 15: 70-85, 1988.
5. Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma of the head and neck: the future is now. Ann Oncol 7: 15-29, 1996.
6. Gueritte-Voegelein F, Guenard D, Lavelle F et al: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-8, 1991.
7. Ringel I, Horowitz SB: Studies with RP 56976 (taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Instil 83: 288-91, 1991
8. Riou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Com 187: 164-70, 1992.
9. Hanauske AR, Degen D, Hilsensbeck SG et al: Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 3: 121-4, 1992.
10. Kelland LR, Abel G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-50, 1992
11. Bissery MC, Guenard D, Gueritte-Voegelein F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503) a taxol analogue. Cancer Res 51: 4845-52, 1991.
12. Boven E, Venema-Gaberscek E, Erkelens CAM et al: Anti-tumor activity of Taxotere (RP 56976, NSC 628503), a new taxol analog in experimental ovarian cancer. Ann Oncol 4: 321-4, 1993.
13. Braakhuis B, Hill B, Dietal M et al: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumor and normal bone marrow cells. Anticancer Res 14: 205-8, 1994.
14. Valero V: Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24 suppl: 1-8, 1997.
15. Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdel S, van Hoesel Q: Phase II studies of docetaxel in the treatment of various solid tumours. Eur J Cancer 31 A, suppl 4: S21-S24, 1995.